https://www.optimumcomms.com/wp-content/uploads/2023/12/Poolbeg_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-02-15 08:37:272024-02-15 08:37:27Poolbeg Pharma plc – Board Role Change and Launch of Employee Performance Incentive Plan
https://www.optimumcomms.com/wp-content/uploads/2023/12/Poolbeg_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-02-15 08:37:272024-02-15 08:37:27Poolbeg Pharma plc – Board Role Change and Launch of Employee Performance Incentive Plan
https://www.optimumcomms.com/wp-content/uploads/2024/01/DelSiTech_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-02-13 08:08:102024-02-13 08:08:10DelSiTech and Tolmar Announce Global License and Development Agreement
https://www.optimumcomms.com/wp-content/uploads/2023/12/Poolbeg_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-02-12 08:38:242024-02-12 08:38:24Poolbeg Pharma plc – Independent Research Confirms >$10bn Market Opportunity for POLB 001 as a Preventative Therapy for Cancer Immunotherapy-Induced Cytokine Release Syndrome (CRS)
https://www.optimumcomms.com/wp-content/uploads/2024/02/Alys_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-02-12 08:19:252024-02-12 08:40:35Alys Pharmaceuticals launches with $100M financing from Medicxi to advance Immuno-Dermatology focused pipeline
https://www.optimumcomms.com/wp-content/uploads/2023/06/Vicore_Pharma_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-02-09 08:08:432024-02-13 08:10:09Vicore and Nippon Shinyaku Enter into an Exclusive License Agreement to Develop and Commercialize C21 in Japan
https://www.optimumcomms.com/wp-content/uploads/2023/08/Invizius_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-02-07 08:36:542024-02-07 08:36:54Invizius Treats First Patients in First-In-Human Phase 1 Clinical Study of Lead Dialysis Product H-Guard®
https://www.optimumcomms.com/wp-content/uploads/2023/12/Biocomposites_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-02-07 08:35:252024-02-07 08:35:25Biocomposites announces two new Phase II clinical trials of STIMULAN VG – a calcium matrix antibiotic carrier mixed with vancomycin and gentamicin – in the U.S.
https://www.optimumcomms.com/wp-content/uploads/2023/06/Novo_Holdings23_Logo_300x180px-80x80-4.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-02-06 08:39:582024-02-07 08:40:10Novo Holdings invests in Manipal Hospitals, a leading private hospital chain in India
https://www.optimumcomms.com/wp-content/uploads/2023/02/Neophare_Logo_300px-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-02-01 08:38:352024-02-01 08:38:35NeoPhore raises an additional £9.6m (USD $12.2m) Series B financing extension to further progress drug discovery pipeline
https://www.optimumcomms.com/wp-content/uploads/2023/02/Neuraxpharm_Logo_300px-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-01-26 13:00:232024-01-26 13:53:42Update on Regulatory Review of leriglitazone in the EU
https://www.optimumcomms.com/wp-content/uploads/2023/06/Breye_Logo_300x180px-80x80-6.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-01-25 08:39:122024-01-25 08:39:12Breye Therapeutics Commences Oral Dosing of Danegaptide in Patients with Diabetic Retinopathy
https://www.optimumcomms.com/wp-content/uploads/2023/12/Vesper_Bio_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-01-23 09:33:062024-01-23 09:33:06Vesper Bio awarded grant by The Michael J. Fox Foundation to assess sortilin inhibitors in the treatment of Parkinson’s disease
https://www.optimumcomms.com/wp-content/uploads/2023/06/Novo_Holdings23_Logo_300x180px-80x80-4.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-01-23 08:41:062024-02-07 08:43:00Novo Holdings announces pre-IPO investment in Medi Assist, the top health benefits’ administrator in India
https://www.optimumcomms.com/wp-content/uploads/2023/07/SynendosTx_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-01-18 08:56:142024-01-18 08:56:14Synendos Therapeutics AG Granted EMA Clinical Trial Authorisation for first-in-class Endocannabinoid System modulator, SYT-510
https://www.optimumcomms.com/wp-content/uploads/2023/12/Poolbeg_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-01-17 08:38:172024-01-17 08:38:17Poolbeg Pharma plc – Further Data Confirms POLB 001’s Potential in Cancer Immunotherapy-Induced Cytokine Release Syndrome (CRS)
https://www.optimumcomms.com/wp-content/uploads/2023/02/AMSilk_Logo_300px-2.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-01-17 08:37:422024-01-17 08:37:42AMSilk and 21st.BIO announce partnership to accelerate the production of advanced materials made from spider silk-based proteinsWe’d love to hear from you
For more information about Optimum Strategic Communications, please get in touch.
